Skip to main content
Drugs - Real World Outcomes logoLink to Drugs - Real World Outcomes
. 2020 Feb 28;7(1):85. doi: 10.1007/s40801-020-00184-w

Correction to: Once‑Monthly Long‑Acting Injectable Aripiprazole for the Treatment of Patients with Schizophrenia and Co‑occurring Substance Use Disorders: A Multicentre, Observational Study

Nestor Szerman 1,✉, Ignacio Basurte-Villamor 1, Pablo Vega 2, Jose Martinez-Raga 3, Carlos Parro-Torres 4, Julia Cambra Almerge 5, Lara Grau-López 6, Mario De Matteis 4, Francisco Arias 7
PMCID: PMC7060974  PMID: 32112360

Correction to: Drugs - Real World Outcomes 10.1007/s40801-020-00178-8

Page 5, Discussion section, column 2, line 11. The following sentence that previously read:

“A randomized, 1-year follow-up study comparing LAI aripiprazole with LAI paliperidone in patients with psychosis, mostly schizophrenia, and SUD reported a large effect of the change from baseline in the CGI severity score, from 5.9 to 2.4 for LAI aripiprazole and from 5.7 to 2.6 for LAI risperidone [29]”.

should read:

“A randomized, 1-year follow-up study comparing LAI aripiprazole with LAI paliperidone in patients with psychosis, mostly schizophrenia, and SUD reported a large effect of the change from baseline in the CGI severity score, from 5.9 to 2.4 for LAI aripiprazole and from 5.7 to 2.6 for LAI paliperidone [29]”.

The original article has been corrected.


Articles from Drugs - Real World Outcomes are provided here courtesy of Springer

RESOURCES